Vericel (US:VCEL)2026-01-13 14:11Financial Estimates and Results - The company issued a press release on January 13, 2026, providing preliminary estimates for full-year 2025 revenue, net income, gross margin percentage, and adjusted EBITDA margin[4] - Preliminary estimates indicate that the company's cash and investments balance as of December 31, 2025, will be reported[4] - The financial statements for the year ended December 31, 2025, have not been finalized or audited, and actual results may differ materially from preliminary estimates[5] - PricewaterhouseCoopers LLP has not audited or reviewed the preliminary financial data provided by the company[7] - The preliminary financial data is the responsibility of the company's management and should not be relied upon without caution[5] - The company has not disclosed specific figures for revenue or net income in the provided documents[4] Conference Participation - Vericel Corporation will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 a.m. Pacific Time[4] Regulatory Information - The company is not classified as an emerging growth company under the Securities Act of 1933[3] - The information in this report is not deemed "filed" under the Securities Exchange Act of 1934[8] - The press release titled "Vericel Announces Preliminary 2025 Financial Results and Business Updates" is included as Exhibit 99.1[9]